Table 2.
Naturally occurring peptides (NOP) from buffalo (B), Holstein cross (HX), Indigenous cattle (IC) and Red Chittagong Cattle (RCC) milk
| EMW | Peptide | Reported bioactivity1 | Protein | B | HX | IC | RCC |
|---|---|---|---|---|---|---|---|
| 1379.80 |
|
Opoid activity | αs1-CN | + | + | − | − |
| 1740.00 |
|
ACE inhibitory | αs1-CN | − | + | − | − |
| 1896.12 |
|
ACE inhibitory | αs1-CN | − | + | − | − |
| 1957.06 |
|
ACE inhibitory and Immunomodulating | αs1-CN | − | + | − | − |
| 2012.98 |
|
ACE inhibitory and Immunomodulating | αs1-CN | − | + | − | − |
| 2048.03 |
|
CPP; Mineral nutrition | αs1-CN | − | + | − | − |
| 2055.99 |
|
ACE inhibitory and Immunomodulating | αs1-CN | − | + | − | − |
| 2064.09 |
|
CPP; Mineral nutrition | αs1-CN | − | − | + | − |
| 2143.12 |
|
ACE inhibitory and Immunomodulating | αs1-CN | − | + | − | − |
| 2215.04 |
|
ACE inhibitory and Immunomodulating | αs1-CN | − | + | − | − |
| 2826.64 |
|
Opoid activity | αs1-CN | − | + | − | − |
| 1250.74 |
|
ACE inhibitory | αs2-CN | − | + | − | − |
| 1385.67 |
|
CPP; Mineral nutrition | αs2-CN | − | + | − | + |
| 2064.10 |
|
CPP; Mineral nutrition | αs2-CN | − | + | − | − |
| 2159.03 |
|
ACE inhibitory and Immunomodulating | αs2-CN | − | + | − | − |
| 2231.04 |
|
ACE inhibitory and Immunomodulating | αs2-CN | − | + | − | − |
| 1313.74 |
|
Opoid activity | β-CN | + | − | − | − |
| 1362.82 |
|
ACE inhibitory | β-CN | + | − | − | − |
| 1378.83 |
|
ACE inhibitory | β-CN | − | + | − | − |
| 1409.90 |
|
Antihypertensive | β-CN | − | + | − | − |
| 1441.79 |
|
Opoid activity | β-CN | + | − | − | − |
| 1484.75 |
|
ACE inhibitory | β-CN | + | − | − | − |
| 1493.96 |
|
Antihypertensive | β-CN | − | + | − | − |
| 1542.83 |
|
Opoid activity | β-CN | + | − | − | − |
| 1554.87 |
|
ACE inhibitory | β-CN | − | + | − | − |
| 1588.92 |
|
ACE inhibitory | β-CN | + | − | + | + |
| 1716.93 |
|
ACE inhibitory | β-CN | + | − | − | + |
| 1717.00 |
|
ACE inhibitory | β-CN | − | + | + | + |
| 1719.10 |
|
ACE inhibitory | β-CN | − | + | − | − |
| 1741.98 |
|
Opoid activity | β-CN | + | − | − | − |
| 1780.95 |
|
ACE inhibitory | β-CN | + | + | − | − |
| 1880.00 |
|
ACE inhibitory | β-CN | + | − | − | − |
| 1888.98 |
|
Opoid activity | β-CN | + | − | − | − |
| 1993.14 |
|
ACE inhibitory | β-CN | + | − | − | − |
| 2125.08 |
|
ACE inhibitory | β-CN | − | + | − | − |
| 2141.04 |
|
ACE inhibitory | β-CN | − | + | − | − |
| 2236.20 |
|
Opoid activity | β-CN | + | − | − | − |
| 2374.40 |
|
ACE inhibitory | β-CN | − | + | − | − |
| 2406.28 |
|
ACE inhibitory | β-CN | − | + | − | − |
| 2537.50 |
|
ACE inhibitory | β-CN | − | + | − | − |
| 3720.21 |
|
ACE inhibitory and Immunomodulating | β-CN | − | + | − | − |
2
Marked fragment in these peptides are also known as β-Casomorphin-5; EMW, experimental molecular weight; +, present; −, absent; ACE, angiotensin converting enzyme; CPP, caseinophospho peptide; CN, casein; Grey/italic and underlined/* marked segments are the reported bioactive fragments.